retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial A review of an investigational drug retatrutide, a novel agent for the treatment of | European Journal of Clinical Pharmacology Lilly's triple agonist delivers up
Pay in 4 interest-free payments of $6.12 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
























